10/28/2026
As a member of Rasopathy Network, we are excited to share that Mount Sinai has announced BabyMERIT, the first NIH-funded U.S. phase 3 clinical trial to study the MEK inhibitor (Trametinib) in babies with life threatening CFC syndrome and other RASopathy-associated hypertrophic cardiomyopathy. This is a major milestone to celebrate.
We thank Dr. Bruce Gelb and Dr. Jane Newburger for their dedication and perseverance to make this study happen!
Moving beyond case studies, this prospective clinical trial is expected to generate rigorous evidence on the effects of using RAS pathway targeted drug treatments for a non-cancer indication in RASopathies. Proof of this concept will de-risk MEK inhibitor treatment and could even open doors to a broader scope of use.
RASopathies Network